INTENSITY THERAPEUTICS INC

INTSNASDAQ

🏆 #4943 by market capUS Equity

$976.24▲ $25.09 (+2.57%)

Simulated price

🔔

Track INTS

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 2.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$12M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Good

No chart data available for INTS.

Trading Snapshot

Day Range: $969.75 – $984.76
52-Week Range: $3.51 – $43.50
Volume: $3.17B
Avg Volume: $2.24B
Shares Outstanding: 2.7M
Next Earnings: Nov 13, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $575,301
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.93
Dividend Yield: —
Dilution (1yr): +2254.6%

Why Investors Own INTS

✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INTENSITY THERAPEUTICS INC

INTS

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$12M▼ −27.8% YoY

Free Cash Flow

−$9M▼ −39.3% YoY

Shares Outstanding

13.6M▲ +2254.6% YoY

Net Cash

$12M▲ +$9M YoY

StockOtter · stockotter.space

About INTENSITY THERAPEUTICS INC

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.

🦦